Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
235 studies found for:    Open Studies | "Macular Degeneration"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
Condition: Macular Degeneration
Intervention: Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
2 Recruiting Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal
Condition: Age-Related Macular Degeneration
Intervention:
3 Recruiting A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: DE-122
4 Not yet recruiting Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Device: Ocusweep system
5 Recruiting Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
Condition: Age Related Macular Degeneration
Intervention: Drug: Aflibercept
6 Recruiting Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Condition: Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
7 Recruiting Proton Radiation Therapy for Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Radiation: Proton radiation
8 Recruiting Study of Dark Adaptation in Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention:
9 Recruiting Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration
Condition: Neovascular Age-related Macular Degeneration
Intervention: Biological: TK001
10 Recruiting OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
Condition: Wet Macular Degeneration
Interventions: Drug: Ranibizumab;   Drug: OZURDEX
11 Recruiting Study of DS-7080a for the Treatment of Neovascular Age-Related Macular Degeneration
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: DS-7080a;   Drug: Ranibizumab
12 Recruiting A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).
Condition: Neovascular Macular Degeneration
Intervention: Drug: Aflibercept
13 Recruiting Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases
Conditions: Macular Degeneration;   Stargardt's Macular Dystrophy
Intervention: Procedure: Subretinal transplantation
14 Recruiting Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
15 Recruiting A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: abicipar pegol;   Drug: ranibizumab;   Other: sham procedure
16 Recruiting Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab ITV injection;   Drug: Ranibizumab through RPDS Implant
17 Recruiting Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Ranibizumab 0.5mg
18 Recruiting To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
19 Recruiting Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Intervention: Drug: Lucentis
20 Recruiting Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)
Condition: Stage 3 Age Related Macular Degeneration (AREDS Classification)
Intervention: Device: MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.